Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 2/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23325684 | 1.00 | CTSS (0.41) | CTSSCTSKNR1H2AAK1ANPEP | |
| SCHEMBL26805423 | 0.93 | CTSK (0.40) | CTSSCTSKAAK1ANPEPSLC1A3 | |
| SCHEMBL28764792 | 0.93 | CTSK (0.43) | CTSSCTSKAAK1SLC1A3SLC1A2 | |
| SCHEMBL20244849 | 0.91 | CTSK (0.45) | CTSSCTSKSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL22090642 | 0.91 | CTSK (0.45) | CTSSCTSKSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL19376814 | 0.91 | CTSS (0.36) | CTSSCTSKNR1H2AAK1ANPEP | |
| SCHEMBL17643592 | 0.91 | CTSS (0.36) | CTSSCTSKNR1H2AAK1ANPEP | |
| SCHEMBL486372 | 0.89 | CPN1 (0.41) | CTSSCTSKNR1H2AAK1ANPEP | |
| SCHEMBL18481441 | 0.87 | LMNA (0.37) | CTSSCTSKAAK1NOS1NOS3 | |
| Hydrochloric Acid SCHEMBL20235918 | 0.86 | LMNA (0.36) | CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-08-15 | — | — | US | disclosed |
| US-11897880-B2 | 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-13 | — | — | US | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
| EP-1381595-B1 | BIS(TRIFLUOROMETHYL)HYDANTOINS AS INTERMEDIATES FOR PHARMACEUTICALLY ACTIVE INGREDIENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1373249-B1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTIINFLAMATORY AGENT | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-6794517-B2 | AS CHEMICAL INTERMEDIATE TO FORM DRUGS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-21 | — | — | US | disclosed |
| EP-1381595-A1 | BIS(TRIFLUOROMETHYL)HYDANTOINS AS INTERMEDIATES FOR PHARMACEUTICALLY ACTIVE INGREDIENTS | Aventis Pharma Deutschland GmbH (DE) | 2004-01-21 | — | — | EP | disclosed |
| US-6680333-B2 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; ANTIALLERGENS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-20 | — | — | US | disclosed |
| EP-1373249-A1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTINFLAMATORY AGENT | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| US-20030073723-A1 | Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-04-17 | — | — | US | disclosed |
| US-20020183374-A1 | Bis(trifluoromethyl)hydantoins as intermediates for pharmaceutically active ingredients | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-05 | — | — | US | disclosed |
| WO-2002072573-A1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTINFLAMATORY AGENT. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002072557-A1 | BIS(TRIFLUOROMETHYL)HYDANTOINS AS INTERMEDIATES FOR PHARMACEUTICALLY ACTIVE INGREDIENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897880-B2 | 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors | F2, F13B, SERPINE1 | CTSS 1445/4885CTSK 466/4885NR1H2 1979/4885 |
| US-20030073723-A1 | Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | VCAM1, ITGA4, ITGA1 | CTSS 2174/4885CTSK 1258/4885NR1H2 1226/4885 |
| US-20020183374-A1 | Bis(trifluoromethyl)hydantoins as intermediates for pharmaceutically active ingredients | HRH1, ALDH7A1, HRH4 | CTSS 636/4885CTSK 876/4885NR1H2 3356/4885 |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | CTSS 7/4885CTSK 50/4885NR1H2 3587/4885 |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | CTSS 7/4885CTSK 43/4885NR1H2 4588/4885 |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | CTSS 7/4885CTSK 43/4885NR1H2 4588/4885 |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | CTSS 7/4885CTSK 43/4885NR1H2 4588/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | CTSS 7/4885CTSK 46/4885NR1H2 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.